502 related articles for article (PubMed ID: 33398362)
21. Therapy with RAS inhibitors during the COVID-19 pandemic.
Spaccarotella C; Mazzitelli M; Migliarino S; Curcio A; De Rosa S; Torti C; Indolfi C
J Cardiovasc Med (Hagerstown); 2021 May; 22(5):329-334. PubMed ID: 33795584
[TBL] [Abstract][Full Text] [Related]
22. RAAS Blockade and COVID-19: Mechanistic Modeling of Mas and AT1 Receptor Occupancy as Indicators of Pro-Inflammatory and Anti-Inflammatory Balance.
Melissa Hallow K; Dave I
Clin Pharmacol Ther; 2021 Apr; 109(4):1092-1103. PubMed ID: 33506503
[TBL] [Abstract][Full Text] [Related]
23. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection in South Korea.
Son M; Seo J; Yang S
Hypertension; 2020 Sep; 76(3):742-749. PubMed ID: 32654557
[TBL] [Abstract][Full Text] [Related]
24. Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.
Wang JJ; Edin ML; Zeldin DC; Li C; Wang DW; Chen C
Pharmacol Ther; 2020 Nov; 215():107628. PubMed ID: 32653530
[TBL] [Abstract][Full Text] [Related]
25. The interacting physiology of COVID-19 and the renin-angiotensin-aldosterone system: Key agents for treatment.
Lumbers ER; Head R; Smith GR; Delforce SJ; Jarrott B; H Martin J; Pringle KG
Pharmacol Res Perspect; 2022 Feb; 10(1):e00917. PubMed ID: 35106954
[TBL] [Abstract][Full Text] [Related]
26. Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System.
Edmonston DL; South AM; Sparks MA; Cohen JB
Adv Chronic Kidney Dis; 2020 Sep; 27(5):404-411. PubMed ID: 33308506
[TBL] [Abstract][Full Text] [Related]
27. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease.
Tomasoni D; Italia L; Adamo M; Inciardi RM; Lombardi CM; Solomon SD; Metra M
Eur J Heart Fail; 2020 Jun; 22(6):957-966. PubMed ID: 32412156
[TBL] [Abstract][Full Text] [Related]
28. Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients.
Baral R; White M; Vassiliou VS
Curr Atheroscler Rep; 2020 Aug; 22(10):61. PubMed ID: 32830286
[TBL] [Abstract][Full Text] [Related]
29. Potential Implications of Angiotensin-converting Enzyme 2 Blockades on Neuroinflammation in SARS-CoV-2 Infection.
Paul D; Mohankumar SK; Thomas RS; Kheng CB; Basavan D
Curr Drug Targets; 2022; 23(4):364-372. PubMed ID: 34732115
[TBL] [Abstract][Full Text] [Related]
30. Impact of renin-angiotensin-aldosterone system inhibitors on COVID-19.
Matsuzawa Y; Kimura K; Ogawa H; Tamura K
Hypertens Res; 2022 Jul; 45(7):1147-1153. PubMed ID: 35581498
[TBL] [Abstract][Full Text] [Related]
31. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.
Rico-Mesa JS; White A; Anderson AS
Curr Cardiol Rep; 2020 Apr; 22(5):31. PubMed ID: 32291526
[TBL] [Abstract][Full Text] [Related]
32. Association of Renin-angiotensin-aldosterone System Inhibitors With Coronavirus Disease 2019 (COVID-19)- Related Outcomes in Korea: A Nationwide Population-based Cohort Study.
Jung SY; Choi JC; You SH; Kim WY
Clin Infect Dis; 2020 Nov; 71(16):2121-2128. PubMed ID: 32442285
[TBL] [Abstract][Full Text] [Related]
33. SARS-CoV-2 and hypertension.
Ravichandran B; Grimm D; Krüger M; Kopp S; Infanger M; Wehland M
Physiol Rep; 2021 Jun; 9(11):e14800. PubMed ID: 34121359
[TBL] [Abstract][Full Text] [Related]
34. Cardiovascular Damage in COVID-19: Therapeutic Approaches Targeting the Renin-Angiotensin-Aldosterone System.
Lumpuy-Castillo J; Lorenzo-Almorós A; Pello-Lázaro AM; Sánchez-Ferrer C; Egido J; Tuñón J; Peiró C; Lorenzo Ó
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899833
[TBL] [Abstract][Full Text] [Related]
35. COVID-19 Therapeutics Why Not Angiotensin Receptor Blockers (ARBs)?
Hariharan TS
J Assoc Physicians India; 2023 Nov; 71(11):71-75. PubMed ID: 38720500
[TBL] [Abstract][Full Text] [Related]
36. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.
Sarzani R; Giulietti F; Di Pentima C; Giordano P; Spannella F
Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L325-L336. PubMed ID: 32639866
[TBL] [Abstract][Full Text] [Related]
37. The Interplay Between the Immune System, the Renin-Angiotensin-Aldosterone System (RAAS), and RAAS Inhibitors May Modulate the Outcome of COVID-19: A Systematic Review.
Naveed H; Elshafeey A; Al-Ali D; Janjua E; Nauman A; Kawas H; Kaul R; Saed Aldien A; Elshazly MB; Zakaria D
J Clin Pharmacol; 2021 Aug; 61(8):987-1000. PubMed ID: 33635546
[TBL] [Abstract][Full Text] [Related]
38. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
Kreutz R; Abd El-Hady Algharably E; Ganten D; Messerli F
Dtsch Med Wochenschr; 2020 May; 145(10):682-686. PubMed ID: 32323279
[TBL] [Abstract][Full Text] [Related]
39. Manipulation of ACE2 expression in COVID-19.
Chaudhry F; Lavandero S; Xie X; Sabharwal B; Zheng YY; Correa A; Narula J; Levy P
Open Heart; 2020 Dec; 7(2):. PubMed ID: 33443121
[TBL] [Abstract][Full Text] [Related]
40. Coronavirus disease 2019, hypertension, and renin-angiotensin-aldosterone system inhibitors.
Rizk JG; Sanchis-Gomar F; Henry BM; Lippi G; Lavie CJ
Curr Opin Cardiol; 2022 Sep; 37(5):419-423. PubMed ID: 35913369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
